Sep 16,2024

Brand New Free To use Type 1 Diabetes in Schools Training Platform Launched Today!

DigiBete has launched a new Diabetes in Schools Training Platform to help teachers and school staff in primary and secondary schools better understand and support students with Type 1 diabetes. The platform, co-designed with healthcare professionals, young people, teachers, and parents, offers comprehensive training on key topics such as managing Type 1 diabetes, diabetes technology like insulin pumps and glucose monitors, and the importance of mobile phone accessibility for students. This initiative, in collaboration with Leeds Children’s Hospital and several diabetes organizations, aims to improve both the physical and emotional well-being of young students with diabetes.

PRODUCT

#cgm

#insulin pump

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 10,2024

Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes

DarioHealth published a new study in Frontiers in Endocrinology demonstrating how physical activity, specifically walking, mitigates the impact of depression on blood glucose levels in individuals with type 2 diabetes (T2D) or prediabetes. The study analyzed data from 989 Dario members who tracked their steps and blood glucose (BG) levels over 12 months. Key findings showed that members with depression had higher average BG levels, but walking significantly reduced these levels., and a statistically significant link was found between depression and BG levels, which was mediated by the number of daily steps. The study supports integrating physical activity, such as walking, into treatment protocols for T2D and depression.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 12,2024

Dario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes

DarioHealth Corp. announced the integration of condition-specific communities and peer groups with personalized navigation into its cardiometabolic solution, enhancing patient engagement and outcomes. This marks a milestone in combining Dario's digital health platform with Twill's community-driven approach, which leverages expert guidance and peer support to improve mental and physical health. Dario's platform, which addresses chronic conditions like diabetes, hypertension, and weight management, now allows users to join peer groups, access experts, and engage with personalized content. These features aim to foster social support, enriching user engagement and improving health outcomes over time.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 08,2024

DarioHealth Reports Second Quarter 2024 Financial and Operating Results

DarioHealth  reported financial results for the second quarter 2024. Dario's B2B2C channel grew 60% sequentially over the first quarter of 2024, and 315% over the second quarter of 2023, primarily due to Aetna customer sign on, expansions of existing customer contracts, new customer launches, and the addition of Twill, revenues following our acquisition of Twill in the first quarter of 2024. The company is confident in their ability to meet the target of cash flow breakeven by the end of 2025, supported by recent progress in the core high margin B2B2C channel that reached $21.6 million in annual recurring revenues (ARR). Dario also reported that they have 9 clients already implementing the GLP-1 program and and several others in the pipeline. They signed agreements to expand with a health plan customer and other off-cycle employers, which are anticipated to launch this year. Revenues for the second quarter ended June 30, 2024, were $6.26 million, a 1.7% increase from $6.15 million for the second quarter ended June 30, 2023, and an increase of 8.6% from $5.76 million for the first quarter of 2024. 

View Analyst & Ambassador Comments
Go to original news
Sep 03,2024 TOP STORY

embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes

Embecta announced it has received 510(k) clearance from the FDA for its proprietary disposable insulin delivery system. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth® wireless technology with a color touchscreen designed to create a simplified interface and user experience.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 09,2024 TOP STORY

Weight loss injections now available across England on the NHS

Oviva announced that it can now offer weight loss injections (GLP-1s) to eligible patients across England as part of its specialist weight management program. This service, accessible at no cost to patients referred by their GP, is a significant development for the 4.2 million people eligible for weight management support. Previously, access to these treatments through the NHS was limited to only 35,000 spots and depended on location. This move aims to address barriers to treatment for people living with obesity by providing easier access to innovative, NICE-approved weight loss medications. Oviva encourages individuals to check their eligibility on its website and seek GP referrals to its Tier 3 Weight Management Programme.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 31,2024 TOP STORY

Tandem Diabetes Care, Dexcom announce t:slim X2 Insulin Pump availability in Canada

Tandem Diabetes Care and Dexcom announced the updated t:slim X2 insulin pump software is compatible with both Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada. This integration allows users of the t:slim X2 insulin pump with Control-IQ technology to have even more choice in how they manage their diabetes. Commercial availability is expected to begin this fall. Tandem will email instructions to all users in Canada with an in-warranty t:slim X2 pump to offer the option to choose between Dexcom G7 and Dexcom G6 via a free remote software update. New customers will receive t:slim X2 pumps pre-loaded with the updated software.

COLLABORATION PARTNERSHIP

#connected device

#closed loop

View Analyst & Ambassador Comments
Go to original news
Sep 09,2024

Sustained 3-Year Improvement of Glucose Control With Hybrid Closed Loop in Children With Type 1 Diabetes While Going Through Puberty

The study aims to evaluate the impact of prolonged hybrid closed loop (HCL) use in children with type 1 diabetes (T1D) on glucose control and BMI throughout pubertal progression. The researchers used a prospective multicenter extension study following the Free-Life Kid AP (FLKAP) HCL trial. The 9-month previously reported FLKAP trial included 119 prepubertal children (aged 6–12 years). During the extension study, participants could continue to use HCL for 30 months (M9 to M39). One hundred seventeen children completed the extension study, with mean age 10.1 years (minimum to maximum, 6.8–14.0) at the beginning. Improvement of HbA1c obtained in the FLKAP trial was significantly sustained during extension and did not differ between children who entered puberty at M24 and patients who remained prepubertal. The results showed that prolonged use of HCL can safely and effectively mitigate impairment of glucose control usually associated with pubertal progression without impact on BMI in children with T1D.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 26,2024 TOP STORY

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

 DexCom announced that Stelo, the first over-the-counter glucose biosensor in the U.S., is available for purchase without a prescription at Stelo.com. Stelo is a small biosensor(15-day wear time) worn on the back of the upper arm that leverages Dexcom’s  glucose sensing technology. It is specifically designed to provide the 125 million Americans with Type 2 diabetes not using insulin and those with prediabetes with powerful, personalized glucose insights sent directly to a smartphone, revealing how food, exercise and sleep can affect glucose. Dexcom offers two payment models for the users: Pay-as-you-go ($99 for a single pack of two sensors total wear time up to 30 days); and Monthly subscription (Pay $89 per month for an ongoing subscription, with two sensors (total wear time up to 30 days).

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 13,2024

State of digital health investment, part 3: AstraZeneca

In an interview with MobiHealthNews, Sonny Shergill, vice president of commercial digital health at AstraZeneca, discussed the company's evolving approach to digital health investments and partnerships. Shergill highlighted how AstraZeneca is expanding its focus on using digital health to enhance life sciences research, support healthcare providers, and engage patients. While the company remains primarily a biopharmaceutical organization, it increasingly collaborates with digital health providers to extend the value of its treatments. AstraZeneca’s strategy involves both early-stage investments through its A. Catalyst Network and partnerships with more established digital health companies.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES